Company intelligence / Profile preview

Suzhou Raymon Pharmaceuticals Co. Ltd.

Ownership: Private
Development stage: Preclinical

Overview

Suzhou Raymon Pharmaceuticals, founded in Suzhou, China in 2018, focuses on innovative drug development for ophthalmic diseases. The company has at least one candidate, RMP-A03 ocular suspension, in clinical trials targeting pterygium. It also holds patents related to novel purine derivatives with potential anticancer applications. The company remains private and active as of May 2025.

Therapeutic areas: OphthalmologyOncology
Modalities: Small moleculesOcular suspensions
Industry: Biotech

Drug pipeline

1 asset

Heterobicyclic metalloprotease inhibitor

Pre-clinical

Indications: Rheumatoid arthritis, Osteoarthritis, Cancer, Multiple sclerosis, Chronic obstructive pulmonary disease

Partnerships

WuXi AppTec/WuXi Clinical – partnered for Phase II trial services with RMP-A03

Beyond the preview

Go deeper on Suzhou Raymon Pharmaceuticals Co. Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Raymon Pharmaceuticals Co. Ltd..

Explore the full profile